# Efficacy of domperidone and/or omeprazole in the treatment of gastroesophageal reflux (GOR) in children - a comparative study

Submission date 30/09/2004	<b>Recruitment status</b> No longer recruiting	<ul> <li>Prospectively registered</li> <li>Protocol</li> </ul>
<b>Registration date</b> 30/09/2004	<b>Overall study status</b> Completed	<ul> <li>Statistical analysis plan</li> <li>Results</li> </ul>
Last Edited 19/10/2016	<b>Condition category</b> Digestive System	<ul> <li>Individual participant data</li> <li>Record updated in last year</li> </ul>

### Plain English summary of protocol

Not provided at time of registration

## Contact information

Type(s) Scientific

Contact name Prof B K Sandhu

#### **Contact details**

C/O Research & Effectiveness Department Level 1, The Old Building **Bristol Royal Infirmary** Malborough Street Bristol United Kingdom BS2 8HW +44 (0)117 928 3473 r&eoffice@ubht.swest.nhs.uk

# Additional identifiers

EudraCT/CTIS number

**IRAS number** 

ClinicalTrials.gov number

### Secondary identifying numbers

N0264130004

## Study information

#### Scientific Title

Efficacy of domperidone and/or omeprazole in the treatment of gastroesophageal reflux (GOR) in children - a comparative study

#### **Study objectives**

The aim of this study is to document the efficacy of domperidone and/or omeprazole in neurologically normal and abnormal children found to have significant GOR on oesophageal pH monitoring.

#### **Ethics approval required** Old ethics approval format

**Ethics approval(s)** Not provided at time of registration

**Study design** Randomised controlled trial

**Primary study design** Interventional

#### **Secondary study design** Randomised controlled trial

**Study setting(s)** Not specified

**Study type(s)** Not Specified

#### Participant information sheet

#### Health condition(s) or problem(s) studied Gastro-oesophageal reflux disease (GORD)

#### Interventions

Double blind placebo controlled prospective randomised controlled trial. Randomised to: A. Domperidone

B. Omeprazole

C. Combination of both

#### Intervention Type

Drug

**Phase** Not Specified

**Drug/device/biological/vaccine name(s)** Domperidone and omeprazole

**Primary outcome measure** Not provided at time of registration

**Secondary outcome measures** Not provided at time of registration

**Overall study start date** 01/03/2004

**Completion date** 01/05/2006

# Eligibility

Key inclusion criteria

1. Children under 16 2. Reflux index >1

Participant type(s) Patient

**Age group** Child

**Upper age limit** 16 Years

**Sex** Not Specified

**Target number of participants** Not provided at time of registration

**Key exclusion criteria** Not provided at time of registration

Date of first enrolment 01/03/2004

Date of final enrolment 01/05/2006

# Locations

**Countries of recruitment** England

United Kingdom

**Study participating centre C/O Research & Effectiveness Department** Bristol United Kingdom BS2 8HW

### Sponsor information

**Organisation** Department of Health

#### Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

Sponsor type

Government

Website http://www.dh.gov.uk/Home/fs/en

### Funder(s)

**Funder type** Government

**Funder Name** United Bristol Healthcare NHS Trust

### **Results and Publications**

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration